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Abstract
A major factor contributing to the failure of orthopedic and orthodontic implants is
post-surgical infection. Coating metallic implant surfaces with anti-microbial
agents has shown promise but does not always prevent the formation of bacterial
biofilms. Furthermore, breakdown of these coatings within the human body can
cause release of the anti-microbial drugs in an uncontrolled or unpredictable
fashion. In this study, we used a calcium alginate and calcium phosphate cement
(CPC) hydrogel composite as the base material and enriched these hydrogels with
the anti-microbial drug, gentamicin sulfate, loaded within a halloysite nanotubes
(HNTs). Our results demonstrate a sustained and extended release of gentamicin
from hydrogels enriched with the gentamicin-loaded HNTs. When tested against
the gram-negative bacteria, the hydrogel/nanoclay composites showed a
pronounced zone of inhibition suggesting that anti-microbial doped nanoclay
enriched hydrogels can prevent the growth of bacteria. The release of [3_TD$DIFF]gentamicin
sulfate for a period of five days from the nanoclay-enriched hydrogels would
supply anti-microbial agents in a sustained and controlled manner and assist in
preventing microbial growth and biofilm formation on the titanium implant
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surface. A pilot study, using mouse osteoblasts, confirmed that the nanoclay
enriched surfaces are also cell supportive as osteoblasts readily, proliferated and
produced a type I collagen and proteoglycan matrix.
Keywords: Health sciences, Engineering, Biological sciences, Bioengineering,
Biomedical engineering, Biomaterials
1. Introduction
Dental and orthopedic appliances, devices, and implants (hereafter collectively
termed ‘implants’) have been in widespread use for over fifty years [1,2, 3].
Advances in surgical techniques and population longevity have drastically
increased both the need and demand for dental and orthopedic procedures
worldwide [4]. Dental and orthopedic complaints (dysfunction, impairment,
pain) are the major reason that most Americans seek clinical intervention. In the
United States alone, more than half a million people undergo total joint
replacement each year and over 50 million yearly receive some form of dental
or orthopedic device or implant. Worldwide, total joint replacements have been
estimated at 959,000 annually, including both primary and revision total hip
replacement procedures [5].
Titanium is the most frequently used metal in dental and orthopedic implants
due to its tensile strength, biocompatibility and corrosion resistance [6, 7, 8, 9,
10]. In an ideal situation, the implant is accepted by and integrated into the
surrounding native tissue resulting in a healthy functioning joint. Bacterial
adsorption and surface colonization of the implant surface [11, 12] and failure
of the implant to integrate with surrounding tissues [11, 12, 13] are the leading
cause of implant failure as well as the resulting sequela that affects a patient's
recovery. Resolving an implant infection usually requires that the implant be
entirely removed, surrounding tissue cleaned of infection, and then a second
prosthetic device is implanted. Revision arthroplasties and increased hospital
stays can cost hundreds of thousands of dollars for a single patient. There are
additional drawbacks to replacement surgeries including: inferior recovery
compared to the initial surgery, further postsurgical complications and pain,
reduced host defense, significant lost time from work, altered and restricted
lifestyles, and even death. Current statistics indicate that infection is responsible
for causing implant failure in approximately 1% of hip implants, 4% of knee
implants, and more than 15% of implants associated with orthopedic trauma,
where the wounds are deep, often filled with debris, such as seen in accident or
battlefield injuries [14, 15].
In their original design, titanium implants were designed simply as mechanical
devices; the biological aspects of the implant were a byproduct of stable internal
or external device fixation to surrounding bone or soft tissue [16]. Surface
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adsorption of serum proteins facilitates bacterial adhesion and proliferation on
the implant surface leading to biofilm formation [11, 17]. A biofilm is a
multicellular community of microbes that forms on a solid surface or at a
liquid–air interface [18, 19]. In a biofilm, microbes are densely packed within
a self-assembled extracellular matrix (ECM) that provides protection for resident
bacteria from various environmental agents. This ECM makes embedded
bacteria more resistant to antibiotics than the resident bacteria normally present
in the human body [10]. Often this can lead to the development of a very
resistant biofilm that may increase bacterial pathogenicity and is the major
reason that biofilm formation is responsible for a host of periprosthetic
infections (PPIs) [20]. PPIs occur in approximately 1% to 2% of primary
arthroplasties [21, 22] and can be greater than 10% in secondary arthroplasties
[23, 24].
A common regimen for patients suffering from PPI is multiple surgeries (wound
debridement) and an extended period of antibiotic therapy resulting in suffering
and further disability [1, 25]. To reduce complications from PPI, delivering
antibiotics directly to the implant site rather then systemically through intravenous
injection and/or oral drugs could reduce the outbreak of toxic bacterial strains such
as C. difficile. To control post-surgical infection of commercial implants, many
manufacturers have used antibiotic and silver adsorption [26, 27] anti-bacterial
coatings [28, 29, 30] impregnation [21] or limited anodization with silver
impregnation [13]. However, the release of anti-bacterial and anti-fungals are
short-lived and result in less than maximal antibiotic release or microbial growth
inhibition. Most of these surface modification methods have failed primarily due to
their inability to provide sustained antibacterial effects due to rapid dissolution
from the implant microenvironment. The quick (and excessive) release of
antimicrobials also raises a major health concern as assisting in the growing
emergence of antibiotic/fungal resistant strains [31, 32, 33].
Recently, nanoporous titanium has emerged as a potential nanostructured
surface. It has a low elastic modulus and a nanotopography that can be tailored
to specific dimensions [34, 35, 36]. Through anodization, the nanoporous
surface can be controlled to specific dimensions that promote cytocompatibility
and tissue integration of dental implant surface coatings and orthopedic implants
[37, 38]. Moreover, the nanotube titanium surface can be used to store and then
release a suite of bioactive agents. In this study, titanium, was anodized to
produce nanoporous titanium (NPT) and modified into an anti-infective hydrogel
surface coating. Hydrogel coatings consisted of alginate with calcium phosphate
cement (CPC) and/or chitosan and enhanced with halloysite nanotubes (HNTs)
loaded with an anti-bacterial drug, Gentamicin. The anodized surface of the
titanium would be favorable for the growth of eukaryotic cells and the bacterial
growth would be prevented. Halloysite is chemically an aluminosilicate and
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upon hydration rolls up to form nanotubes with an average length ranging from
1–3 μm and average diameter ranging in 30–70 nm [57, 58]. Use of HNTs as
drug carriers and delivery vehicles for bioactive molecules has been studied and
the release of these molecules form HNTs is sustained [46, 47, 48, 49, 51, 54].
Gentamicin is a heat stable antibiotic used widely in orthopedic surgeries and is
effective against gram-negative bacteria [39]. Gentamicin doped hydrogels were
found to have a sustained release of gentamicin that inhibited the growth of
E. coli bacteria. A pilot study using mouse pre-osteoblasts confirmed that the
hydrogel coatings were cell supportive. The graphical representation of the
titanium-hydrogel composite in Fig. 1 illustrates our concept of an anodized
titanium with an anti-microbial hydrogel coating.
The titanium metal (T) is anodized on the surface to produce a rough and featured
topography (AT). Hydrogel coating (H) which is composed of anti-microbial
agent, Gentamicin, (G) loaded HNTs is coated on to the anodized surface of the
titanium to prevent bacterial (B) attachment and biofilm formation. Gentamicin
will be released in a sustained manner over an extended period of time preventing
the bacteria to grow of the metal implant surface.
2. Experimental
2.1. Materials
Unless otherwise stated, all chemicals for synthesis and physicochemical
analysis were of ACS grade, purchased from Sigma-Aldrich and used as
received without further purification. [4_TD$DIFF]Gentamicin sulfate antimicrobial
susceptibility disks (60 μg/disk) were purchased from Thermo Scientific,
Waltham, MA.
[(Fig._1)TD$FIG]
Fig. 1. Graphical representation of the anti-microbial hydrogel (H) coating applied to anodized
titanium (AT). From left to right, bacteria (B) encounter the anti-microbial hydrogel and released
gentamicin (G) altering their metabolism leading to cell death. T = titanium.
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2.2. Scanning electron microscopy
Hydrogels were lyophilized in preparation for scanning electron microscopic
imaging in order to retain the gel matrix structure. The hydrogel samples were
taken out of the autoclaved RO water and placed on Whatman No. 1 filter paper
to drain out excess water. These partially dried hydrogels were then frozen in
glass beakers at −20 °C overnight before lyophilization. Lyophilization was
carried out using a LabConco Lyophilizer for 36 h. The lyophilized hydrogels
were then imaged using a HITACHI 4800 Scanning Electron Microscope to
reveal details of hydrogel surface. Images were taken at 1 kV and at
magnification ranging from 1.00 mm to 100 μm. The control sample was
alginate only hydrogel beads. The sample hydrogels consisting: alginate/HNTs,
CPC/alginate, and CPC/alginate/chitosan were compared against the control;
alginate only hydrogel beads were used as controls for surface morphology
analysis.
2.3. Loading of halloysite nanotubes
HNTs were mixed with 50 mg/ml solution of gentamicin sulfate and sonicated
continuously for 15 min. Sonicated HNTs were then placed in a vacuum
chamber and vacuum was applied for 2 h alternating with vacuum release. This
process was carried out for 24 h. The loaded HNTs were then vacuum dried and
then given two washes with sterile distilled water to remove traces of
Gentamicin sulfate that might have been coated on the HNTs outer surface.
2.4. Elution study for gentamicin from HNTs and hydrogels
The elution data for gentamicin release from HNTs and hydrogels enhanced
with HNTs was obtained by studying the release for a period of 24 h. The
release was done in simulated body fluid (SBF) buffer (pH 7.5 and temperature
∼25 °C). The gentamicin loaded HNTs were mixed with SBF and then samples
were collected for fixed time intervals. As GS cannot be detected directly by
UV-Visible spectroscopy, an indirect method of detection by ophthalaldehyde
reagent was used. This reagent was prepared by adding 250 mg of
ophthalaldehyde powder to 6.25 ml of 95% methanol. This mixture was
sonicated for 30 min till a clear solution was obtained. 0.3 ml of 2-hydroxy
ethyl mercaptan was added to 56 ml of 0.04 M sodium borate and mixed
thoroughly. Both these mixtures were added, then sonicated for 15 min before
being stored in an amber color container for 24 h. A total of, 1 ml each of
collected gentamicin sample, isopropanol (to prevent sedimentation) and
ophthalaldehyde reagent were mixed and left undisturbed for 20 min at room
temperature. The absorbance for the GS was measured at 333 nm using a
Thermo scientific NanoDrop 2000 [5_TD$DIFF]Spectrophotometer.
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2.5. Preparation of hydrogels
Sodium alginate (2% w/v) when mixed with calcium chloride (1% w/v) forms a
gel matrix by reverse crosslinking. The result is a hydrogel polymer calcium
alginate. The calcium alginate hydrogels were enhanced with CPC. In the
following compositions, CPC refers to a mixture of tetracalcium phosphate
(TTCP) and dicalcium phosphate (DCPA) in 730 mg to 270 mg mixed in
equimolar ratios. The formulation for CPC hydrogels with were:
1. CPC/alginate = 1 gm: 3 ml
2. CPC/alginate/chitosan = 1 gm: 20 mg: 6 ml
The hydrogels with CPCs were also enhanced with 1% w/v HNTs to improve
their material strength. The control groups have alginate only and alginate + 1%
w/v HNTs (Alginate/HNTs) without gentamicin sulfate.
The CPC/alginate and CPC/alginate/chitosan hydrogels were formed by mixing the
CPC, chitosan [8_TD$DIFF]lactate, HNTs and sodium alginate in appropriate proportions and
then dropping the mixture in 1% calcium chloride solution using a syringe with
18½ G needle. The hydrogel beads formed instantaneously upon contact with
calcium chloride solution but were kept in the solution for complete reverse
crosslinking for 15 min. For maintaining hydrated conditions, the hydrogels were
stored in RO autoclaved water.
2.6. Bacterial culture
Single colonies of DH5α strain of E. coli (lab stock) were cultured in
Luria-Bertani (LB) broth liquid medium. The inoculum from the LB broth was
plated onto LB agar and Mueller-Hinton plates under sterile conditions.
2.7. Bacterial inhibition studies
Control and experimental hydrogel beads were kept on the inoculated plates and
these plates were incubated at 37 °C. These plates were then observed for
inhibition zones and compared against [3_TD$DIFF]gentamicin antimicrobial susceptibility
disks.
2.8. Pilot pre-osteoblast study
To assess if the hydrogel coatings would support cell growth and functionality,
3T3 preosteoblasts (ATCC CRL 2593 E1 subclones) were cultured on the
coatings. The experimental samples had CPC/alginate, CPC/alginate/chitosan
and CPC/alginate/chitosan/HNTs hydrogel films. The objective of this study was
to ascertain if the mammalian host tissue cells (3T3 preosteoblasts) can adhere
and grow on the hydrogels. If the mammalian cells would adhere or secrete
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ECM proteins on the hydrogels, this would suggest that the hydrogels support
mammalian cell adhesion, growth and functionality and inhibit bacterial growth.
Standard cell culture protocols were followed and sterile conditions maintained
throughout the culturing, passaging, seeding and experimental time period. The
experimental plates were fixed on days 3, 7, and 14 by adding 95% ethanol. The
fixed plates were then stained for ECM proteoglycans, glycoproteins and
mucopolysaccharides with Alcian Blue stain and for collagen secretion with
Picrosirius Red stain. To quantify the amount of cellular secretions after the
cells adhere, the stain was eluted by destaining the plates in 7% v/v acetic acid
destaining solution. The destained solution from each well was collected and
quantified by UV/Vis spectrophotometry using a NanoDrop 2000
spectrophotometer.
2.9. Statistical analysis
The data from the histochemical analysis (Alcian Blue and Picrosirius Red
staining) was plotted as a graph of means of data points per sample/type/day for
two experimental trials (n = 3 samples per trial) and the samples were
independent of each other. Inferential statistics, such as ANOVA, could not be
used because of the limited sample size; hence, a simple descriptive statistic was
used for the interpretation of the results. The error bars were calculated as the
percent error.
3. Results and discussion
3.1. Surface morphology of hydrogels
Scanning electron microscopy was done on the hydrogel beads to assess the
surface morphology of the beads. A comparison between the hydrogels cryo-SEM
images revealed that the surfaces of hydrogels with HNTs, CPC, and CPC plus
chitosan had a rough and modified surface against a relatively smoother surface of
alginate only hydrogel beads as can be seen in Fig. 2 (A–F). The surface
topography varied in terms of amplitude and heterogeneity.
The alginate only hydrogels Fig. 2A under cryo-SEM shows a very smooth
surface which is almost devoid of any surface features. The alginate only
hydrogel shows some elevations which are gentle and some folds which might
have resulted because of the process of lyophilization. The hydrogels which are
enhanced with other materials like CPC, chitosan, and HNTs have distinctive
surface features like ridges, sharp elevations, and depressions. The surface
features get formed in the hydrogels because of the interactions of the materials
with alginate. Chitosan lactate and HNTs clump in aqueous solutions. In our
method of hydrogel preparation, we employed methods to disperse or
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breakdown these clusters into fine particles and these dispersed particles might
give the hydrogels their unique surface topography as seen in the Fig. 2 B–F.
Eukaryotic mammalian cells prefer a relatively rough surface or a surface with
some features (heterogeneous) for adherence [40, 41]. Experiments using
engineered substrates with nanoscale features have shown the importance of
ECM nanotopography on cellular morphology, adhesion, proliferation, and
differentiation [40, 41, 42](extensively reviewed in [43, 44]). Zhou et al. [45]
showed that on poly(vinyl alcohol) PVA/HNT bionanocomposite surfaces,
osteoblasts exhibited a significantly higher level of adhesion than on neat PVA.
Accordingly, beads with HNTs, CPC, and chitosan have a rough surface that
should be favorable for cell attachment as compared with the smooth alginate
only hydrogel surface.
3.2. Gentamicin sulfate release from halloysite nanotubes and
hydrogels
Gentamicin sulfate was released from HNTs within a period of 48 h in an
experiment samples over 7 days. The graph in Fig. 3 shows that the release
obtained is released in a sustained fashion over the 7-day period.
[4_TD$DIFF]Gentamicin sulfate release from hydrogels was for a period of 5 days
(approximately 48 h), in an experiment that took samples over 7 days. The
graph in Fig. 4 shows that the release obtained in a sustained fashion for 48 h
[(Fig._2)TD$FIG]
Fig. 2. SEM micrographs of the hydrogel coating surfaces (A) alginate only; (B) alginate/HNTs; (C)
CPC/alginate; (D) CPC/alginate/chitosan. At higher magnification, (E and F) HNTs can be seen
protruding from the hydrogel surfaces (E) alginate/HNTs; (F) CPC/alginate/HNTs. Scale bar = 100
microns in A to D and 1 micron in E and F.
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over the 7-day experimental period. The declining amount of GS that is released
from the HNTs cannot be shown in the graph as it is a cumulative release
profile. A cumulative plot was chosen to represent the release of gentamicin
from HNTs as the amount of drug release at a particular time interval is
dependent on the concentration gradient at that particular time point and that in
turn is dependent on how much drug is released at a previous time point.
However, the authors would like to note here that GS was not detectable after
[(Fig._3)TD$FIG]
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Fig. 3. Cumulative gentamicin sulfate release from HNTs showing time (hours) vs. concentration
(mg/ml) (n = 6) with error bars showing percent error (5%).
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Fig. 4. Cumulative graph of gentamicin sulfate release from hydrogels showing time (hours) vs.
concentration (mg/ml) (n = 6) error bars showing percent error (5%).
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48 h of the experiment suggesting that the gentamicin that was loaded in the
HNTs would be exhausted almost entirely or the levels were too low to be
detected by the UV/Vis spectrometry.
The groups studied for the release of GS in Fig. 4 are CPC-1% w/v HNTs + GS
(shown by green square), CPC with 2% v/v GS directly loaded in the CPC (blue
triangle), and HNTs with GS (red diamond). The graph shows the release
kinetics of the GS from these various groups from the HNTs or the hydrogel
directly in pH 7 at room temperature. The curve shows the release of GS that is
adsorbed on the surface of the HNTs as well as the molecules that have been
loaded inside the lumen of the HNTs.
The maximum loading efficiency of HNTs is about 12% of its volume [59]. The
ability of HNTs to encapsulate and provide sustained release has been
demonstrated for a variety of chemical agents, including antiseptics and
antibacterials [46, 47, 48], drugs [49, 50] growth factors [51, 52] and DNA
[53]. In the majority of studies, encapsulation in halloysite significantly reduced
drug release and in the case of BMP-2 (51) allowed release of this growth factor
in picogram range.
Gentamicin-doped HNTs were embedded in poly methyl-methacrylate (PMMA)
beads and PMMA bone cement. Gentamicin and other antibiotics have been
added to cement to improve local antibiotic delivery in addition to intravenous
or oral doses [39, 53, 54, 55, 56]. Commercial-grade PMMA bone cement
formulations release 70% of gentamicin within the first 24 h [54, 55]. Wei et al.
[54] showed that PMMA bone cement doped with gentamicin loaded halloysite
nanotubes released gentamicin in a slow and sustained fashion and did not
compromise composite mechanical strength [54].
In case of GS, the molecule size is relatively smaller when compared to the
HNTs. Gentamicin sulfate used in this study is in solution form and the
molecules would adhere on all the surfaces of the HNTs. The elution patterns
shown in Fig. 3 and Fig. 4 show the possible adsorption patterns on both the
inner and outer surfaces. The initial burst release may be due to the molecules
that have adhered to the outer surface of the HNTs and desorb faster as
compared to the molecules loaded inside the tubes. The extended release of the
drug can be attributed to the slow desorption of the molecules that are loaded in
the inner lumen of the HNTs. Drug release from the lumen is a slow process as
it involves several steps: solvent diffusion into the lumen, drug diffusion in
the solvent in the lumen followed by the diffusion of drug from solvent in the
lumen in to the surrounding solution. As the solvent can only diffuse into the
lumen from the pores (two ends of the nanotube), elution from the lumen may
be delayed to an extended period.
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3.3. Bacterial study
Having shown that our hydrogel coatings can release gentamicin in the range of
0.5–1 mg/ml we initiated a bacterial study using hydrogels, with and without [3_TD$DIFF]
gentamicin sulfate loaded halloysite, conducted on Mueller-Hinton agar plates
cultured with E. coli. The plates were observed after 24 h of incubation at
37 °C. The positive control had a uniform deposition of E. coli growth and the
negative control showed no bacteria growth on it as seen in Fig. 5A and B.
Hydrogels enhanced with the HNTs but without being doped with [3_TD$DIFF]gentamicin
sulfate were placed on the Mueller-Hinton agar plates with E. coli. After 24 h,
no zones of inhibition were observed on the plates as can be seen in Fig. 6
suggesting that the hydrogels themselves are not anti-microbial.
The hydrogels with gentamicin sulfate loaded HNTs produced extensive zones
of growth inhibition as seen in Fig. 7C and D that are comparable with the
gentamicin control disks. The zones of inhibition on the plates with gentamicin
loaded HNT- hydrogels indicate that the anti-bacterial agent released from the
hydrogels is capable of inhibiting the growth of bacteria on the agar plates. The
zones of inhibition in all of these plates, Fig. 6 [9_TD$DIFF] I–IV, have an average diameter
of approximately 1 cm. This can prevent the formation of bacterial colonies and
in turn bacterial films on the implant surface in turn increasing the chances of
infection free implant.
That these hydrogels have antimicrobial properties would suggest that these
hydrogel coatings on implants will decrease the chance of post-surgical
infection. The experiment was conducted for a 7-day period but the gentamicin
was released in 48 h. The points after 48 h show a plateau.
[(Fig._5)TD$FIG]
Fig. 5. (A) Negative control Mueller-Hinton plate and (B) Positive control Mueller-Hinton plate
with E. coli colonies. (–ve = negative control, +ve = positive control, n = 6).
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3.4. Pre-osteoblast pilot study
A pilot study was conducted to identify the hydrogel coating that best supports
cell viability and growth. The response of NIH 3T3 pre-osteoblasts after culture
upon calcium alginate and calcium phosphate cement (CPC) hydrogel
composites, with and without HNTs, was assessed through histochemical
staining for detection of collagen and proteoglycan synthesis. For proteoglycan
detection, the stain Alcian Blue was used. After each coating was stained, the
dye was eluted with a 7% v/v acetic acid destaining solution and quantified by
spectrophotometry. An indirect method of quantification was used instead of a
conventional staining and imaging approach as the scaffold films were too thick
for conventional light microscopy to photodocument cells attached to the
coatings. The difference in acidic polysaccharides secreted by the cells adhered
to the coatings is expressed as absorbance vs. days in culture (Fig. 8). The study
was conducted using triplicates of each sample and repeated twice to check the
reproducibility of results.
[(Fig._6)TD$FIG]
Fig. 6. Bacterial growth inhibition studies. (I) (a) Alginate + HNTs + CPC + chitosan, (b) Alginate
+ HNTs + CPC, (c) Alginate only, and (d) Alginate + HNTs. (II) (a) Gentamicin control disk (60
mg gentamicin) shows a large zone of inhibition. (b) E. coli growing as a continuous lawn. (III)
Mueller-Hinton plate with hydrogels with gentamicin sulfate showing zones of inhibition (top)
alginate + HNTs + CPC + chitosan + gentamicin, (bottom) alginate + HNTs + CPC + gentamicin,
(IV) alginate + HNTs + gentamicin (n = 6).
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Fig. 7. Graph showing the absorbance (at 450-495 nm) of the eluted Alcian Blue stain against the
number of days and different hydrogel composition (n = 6).
[(Fig._8)TD$FIG]
2.2
2.4
2.6
2.8
3
3.2
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
D3 D7 D14
Days
A
bs
or
ba
nc
e
CPC+Alginate+Chitosan
CPC+Alginate+Chitosan+HNTs
CPC+Alginate
Fig. 8. Graph showing the absorbance (at 620–750 nm) of the eluted Picrosirius Red stain against
the number of days (n = 6).
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Alcian Blue staining results shows that the CPC/alginate films had synthesized a
greater amount of proteoglycan day 3 but there was a drop by day 14. The CPC/
alginate films also had comparatively more sulfated ECM than the rest of the films
as shown in Fig. 7 on day 3. The CPC/alginate/chitosan films maintained sulfated
ECM levels relatively equal on days 3, 7 and 14. The CPC/alginate/chitosan/HNTs
films had the least sulfated ECM on day 3 when compared against the other
scaffolds. The levels of sulfated ECM decreased on day 7 but remained relatively
similar on day 14.
To quantify collagen secretion, the Picrosirius Red stain was used to stain cells
on hydrogel coatings. Osteoblasts produce an organic matrix, principally
composed of type I collagen (Osteoid) prior to its mineralization. After
destaining in 7% v/v acetic acid, the eluted stain was quantified through UV/Vis
spectrophotometry. The results are shown in Fig. 8 as collagen secreted by
adherent cells as absorbance plotted against number of days in culture.
Picrosirius Red staining data showed that the CPC/alginate films had
accumulated the less amount of collagen on day 3 but increased by day 7 with a
decrease noted on day 14. The CPC/alginate films also had produced a lesser
amount of collagen when compared with the other two coatings (Fig. 8) In
contrast, CPC/alginate/chitosan films produced an initial higher amount of
collagen which was maintained through day 14. CPC/alginate/chitosan/HNT
films produced the most collagen by day 3 when compared against the other
scaffolds. The levels of collagen remained relatively similar on days 3 and 7
and decreased in amount by day 14. The cumulative supports the observation
that cells on all substrates produced a base organic extracellular matrix.
When we reviewed the histochemical staining data, we observed a relationship
between the amount of ECM proteoglycans and collagen secreted by cells
throughout the 14 day period. CPC/alginate films had accumulated a more
proteoglycan-rich matrix by day 3 but the synthesis of collagen was reduced
when compared with the other hydrogel types. The CPC/alginate/chitosan/HNTs
hydrogel coatings showed the least production of proteoglycan by day 3 by
comparison but assembled a more collagen-rich matrix when compared against
the other hydrogel coatings. Therefore, the two formulations that hold the most
promise for tissue formation are CPC + Alginate + Chitosan and CPC +
Alginate + Chitosan + HNTs.
We used a descriptive statistic in this study that explained the qualitative
significance of the data. The samples were independent of each other and the
values reflect the averages of the readings that were taken per sample for that
particular day in two separate trials. When considering the matrix production of
cells cultured on each hydrogel coating, the most cell supportive hydrogel type
was CPC/alginate/chitosan with both proteoglycan and collagen synthesis
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remaining relatively stable on all the days. The CPC/alginate/chitosan and
CPC/alginate/chitosan/HNT hydrogel film synthesized greater amounts of ECM
proteins throughout the 14-day period with respect to proteoglycan and collagen
secretion. Both hydrogel types produced comparable amounts of proteoglycan
and collagen on days 7 and 14.
5. Conclusions
The anti-microbial agent, [3_TD$DIFF]gentamicin sulfate, was released from halloysite
nanoclay and from hydrogels enriched with this nanoclay for a period of 5 days.
The pattern of [3_TD$DIFF]gentamicin sulfate release from the nanoclay-enriched hydrogels
supplied anti-microbial agents in a sustained manner. The released [3_TD$DIFF]gentamicin
sulfate showed that it inhibits the growth of E. coli on Mueller-Hinton plates for
24 h similar to the [3_TD$DIFF]gentamicin sulfate antimicrobial susceptibility disks (10 μg/
disk). The first 24 h after the surgical implantation of any implant are crucial
and if infection does not set in within these 24 h then chances for implant
stability and acceptance should increase. The pilot cell study using 3T3
preosteoblasts also suggest that the hydrogel coatings will provide a suitable and
cell supportive implant surface for mammalian cells.
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